MedX Health closes $247K final tranche of private placement

News Release

MedX Health Corp. Announces Further Closing of Brokered Private Placement

Mississauga, ON, July 14, 2017 – MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX). The Company announced that, effective July 14, 2017, it closed the second and final tranche of a brokered private placement announced on March 9, 2017, when it entered into an engagement with WCM Capital (the “Agent”). Upon closing of the second tranche (“Closing”), the Company raised gross proceeds of $246,757 to its treasury by issuance of 2,056,306 units (“Units”), comprising 2,056,306 common shares (“Share(s)”) and 2,056,306 common share purchase warrants (“Warrants”), at $0.12 per Unit. Each Warrant entitles the holder thereof to purchase one additional Share during the period expiring July 14, 2020, at $0.20 per Share. At Closing, a total of 114,005 compensation options (the “Compensation Options”) were issued to brokers; each Compensation Option is comprised of a non-transferable broker’s warrant, exercisable for a period of three years, to acquire one Unit at the price of $0.12, comprised of a Share and a Warrant exercisable until July 14, 2020, at a price of $0.20. Broker commissions amounting to a total of $13,680 were also paid in cash from the gross proceeds. The securities issued on July 14, 2017 are restricted from trading before November 15, 2017. The funds raised on Closing, together with the funds raised on the first closing, which took place on April 21, 2017, brings the total amount raised pursuant to the Company’s engagement with the Agent to $1,080,557.

Following this Closing, MedX has 106,695,800 shares outstanding.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIMSYS, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

For further information:

Robert von der Porten / President and CEO MedX Health Corp.